AR and small cell carcinoma: A subset of CRPC may progress to lethal AR-indifferent neuroendocrine/small cell carcinoma (NE/SC) following further AR suppression by the second and third-generation AR inhibitors (e.g., abiraterone, enzalutamide, apalutamide, darolutamide).